Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Study summary

The purpose of this study is to find out whether the study drug tocilizumab is an effective treatment for COVID-19 infection.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedTocilizumab

The study team can explain what participation involves.

Who it may be forCOVID-19

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 28, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Drug: Tocilizumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patient or designated proxy willing and able to provide informed consent prior to enrollment in the study.
COVID-19 PCR positive on nasopharyngeal swab
Aged \>/= 18 years old
Patient hospitalized with newly diagnosed documented severe COVID-19 infection: with respiratory rate \>/= 30 breaths/min OR peripheral capillary oxygen saturation (SpO2) \< 93% on room air for nonintubated pts.
Fever of 38.5 C or suspected respiratory infection
IL-6 level \>/= 80 pcg/ml
Cohort #1 - non intubated Cohort #2 - intubated
Women of childbearing potential must have a negative serum or urine pregnancy test
Patients receiving ongoing steroid therapy are eligible
Patients will be allowed to receive concurrent or sequential treatment with remdesivir

Reasons someone may not be able to joinExclusion criteria

Patients with uncontrolled systemic fungal and bacterial infections
Patients with latent tuberculosis
Patients with known hypersensitivity to tocilizumab or any component of the formulation
Concurrent initiation of steroid therapy is not allowed
Patients with uncrontroled malignant disease, with a life expectancy of 3 months or less

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Cancer CenterNew York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 28, 2025. Always confirm current availability with the study team.

View original record ↗